Clifford Chance advises Rivean Capital's portfolio company To-Increase on its acquisition of AX for Pharma

28 April 2023

Clifford Chance advises Rivean Capital's portfolio company To-Increase on its acquisition of AX for Pharma

International law firm Clifford Chance advised To-Increase, a portfolio company of its long-standing client private equity investor Rivean Capital, on the acquisition of AX for Pharma (AXP) in Italy.

To-Increase is a leading global Independent Software Vendor (ISV) for Microsoft Dynamics 365 (D365) business applications. AXP is another fast-growing Microsoft Dynamics 365 ISV and integrator focused exclusively on SaaS business applications for the pharmaceutical, biotech, and medical device industries. The acquisition of AXP aims to expand To-Increase’s global footprint and strengthen its presence in the process manufacturing vertical. The transaction signed in March and was completed in April. Read more about the transaction here.

The Clifford Chance cross-border team was led by Pieter Leefers and consisted of Robin Traas, Ruben van Diepen (Corporate), Michiel Sunderman, Alec Sanderson and Cile Arnoldy (Tax) and Leen Kranenburg (Notary) in Amsterdam, and Milena Raffaldi, Francesco Romagnoli,Antoaneta Shikerova (Corporate), Luciano Di Via, Antonio Mirabile and Luca Borin (Antitrust), Marina Mobiglia (Employment) and Andrea Sgrilli (Tax) in Milan.